logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Luxshare Precision Industry (02475) will distribute a mid-term dividend of 1.1 yuan per 10 shares on October 22.

date
06:34 25/08/2026
avatar
GMT Eight
Luxshare Precision (02475) announced that it will distribute an interim dividend of 1.1 RMB for every 10 shares on October 22, 2026.
Luxshare Precision Industry (02475) announced that the company will distribute an interim dividend of 1.1 RMB for every 10 shares on October 22, 2026.
Related Articles
HK Stock
TUYA-W (02391) released its interim results, with a net profit of 34.40 million USD, an increase of 45.8% year-on-year.
HK Stock
PERENNIAL INT'L (00725) has sold a total of 40,000 shares of Alibaba.
HK Stock
ANTENGENE-B(06996): ATG-201 for the treatment of B cell-mediated autoimmune diseases has received HREC approval for the Phase I ATTRACT study in Australia.
TUYA-W (02391) released its interim results, with a net profit of 34.40 million USD, an increase of 45.8% year-on-year.
HK Stock
PERENNIAL INT'L (00725) has sold a total of 40,000 shares of Alibaba.
HK Stock
ANTENGENE-B(06996): ATG-201 for the treatment of B cell-mediated autoimmune diseases has received HREC approval for the Phase I ATTRACT study in Australia.
HK Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.